Abstract
Philadelphia-positive (Ph+) B-cell precursor acute lymphoblastic leukemia (BCP–ALL) is a genetically heterogeneous disease with a very poor prognosis. In this study, we analyzed the frequency of supernumerary Ph, trisomy 8, monosomy 7, and del(9p21) by FISH and its relationship with the characteristics of the disease, in 46 BCR/ABL+ adult BCP–ALL patients. The frequency of supernumerary Ph, trisomy 8, monosomy 7 and del(9p21) was 30%, 20%, 15%, and 24%, respectively. Although all patients displayed a BII/common phenotype, supernumerary Ph and trisomy 8 were associated with higher expression of CD19 and CD22 and of CD19, CD34, CD45, and HLA-DR, respectively; in turn, cases with monosomy 7 showed lower CD19, CD22, CD34, and cCD79a and del(9p21)+ blasts were CD13− and CD33−. Overall, similar clinical and hematological features were observed at presentation, independently of the underlying genetic abnormalities. However, relapse-free survival (RFS) was significantly shorter in cases with supernumerary Ph, trisomy 8, and del(9p21), the latter being the most powerful independent prognostic factor for RFS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X, et al., Groupe d'Etude et de Traitement de la Leucemie Aigue Lymphoblastique de l'Adulte (GET-LALA Group. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia – results of the prospective multicenter LALA-94 trial. Blood 2002; 100: 2357–2366.
Cimino G, Elia L, Mancini M, Annino L, Anaclerico B, Fazi P, et al., GIMEMA Group. Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome. Blood 2003; 102: 2014–2020.
Gleissner B, Gokbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, et al., German Multicenter Trials of Adult Acute Lymphoblastic Leukemia Study Group. Leading prognostic relevance of the BCR–ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002; 99: 1536–1543.
Rieder H, Ludwig WD, Gassmann W, Maurer J, Janssen JW, Gokbuget N et al. Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia. Br J Haematol 1996; 95: 678–691.
Thomas X, Thiebaut A, Olteanu N, Danaila C, Charrin C, Archimbaud E et al. Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome. Hematol Cell Ther 1998; 40: 119–128.
Wetzler M, Dodge RK, Mrozek K, Stewart CC, Carroll AJ, Tantravahi R et al. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. Br J Haematol 2004; 124: 275–288.
Heerema NA, Harbott J, Galimberti S, Camitta BM, Gaynon PS, Janka-Schaub G, et al., Acute Lymphoblastic Leukemia Study Groups; ALL-BFM; CoALL; AIEOP; DCLSG; FRALLE; CCG; DFCI; POG; St Jude; UKALL. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia 2004; 18: 693–702.
Preti HA, O'Brien S, Giralt S, Beran M, Pierce S, Kantarjian HM . Philadelphia-chromosome-positive adult acute lymphocytic leukemia: characteristics, treatment results, and prognosis in 41 patients. Am J Med 1994; 97: 60–65.
Ko BS, Tang JL, Lee FY, Liu MC, Tsai W, Chen YC et al. Additional chromosomal abnormalities and variability of BCR breakpoints in Philadelphia chromosome/BCR–ABL-positive acute lymphoblastic leukemia in Taiwan. Am J Hematol 2002; 71: 291–299.
Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G . Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol 1997; 96: 601–610.
Walters R, Kantarjian HM, Keating MJ, Estey EH, Trujillo J, Cork A et al. The importance of cytogenetic studies in adult acute lymphocytic leukemia. Am J Med 1990; 89: 579–587.
Kantarjian H, Talpaz M, Estey E, Ku S, Kurzrock R . What is the contribution of molecular studies to the diagnosis of BCR–ABL-positive disease in adult acute leukemia? Am J Med 1994; 96: 133–138.
Faderl S, Estrov Z, Kantarjian HM, Thomas D, Cortes J, Manshouri T et al. The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia. Cytokines Cell Mol Ther 1999; 5: 159–163.
Primo D, Tabernero MD, Rasillo A, Sayagues JM, Espinosa AB, Chillon MC et al. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities. Leukemia 2003; 17: 1124–1129.
Ortega JJ, Ribera JM, Oriol A, Bastida P, Gonzalez ME, Calvo C, et al., PETHEMA Group, Spanish Society of Hematology. Programa para el Estudio y Tratamiento de las Hemopatias Malignas. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukaemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL. Haematologica 2001; 86: 586–595.
Hernandez JM, del Canizo MC, Cuneo A, Garcia JL, Gutierrez NC, Gonzalez M et al. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol 2000; 11: 441–444.
ISCN 1995. In: Mitelman F (ed). Guidelines for Cancer Cytogenetics, Supplement to: An International System for Human Cytogenetic Nomenclature. S Karger: Basel, 1995.
Espinosa AB, Tabernero MD, Garcia-Macias MC, Primo D, Bernal AG, Cruz JJ et al. Her-2/neu gene amplification in familial vs sporadic breast cancer. Impact on the behavior of the disease. Am J Clin Pathol 2003; 120: 917–927.
Ciudad J, San Miguel JF, Lopez-Berges MC, Vidriales B, Valverde B, Ocqueteau M et al. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1998; 16: 3774–3781.
Tabernero MD, Bortoluci AM, Alaejos I, Lopez-Berges MC, Rasillo A, Garcia-Sanz R et al. Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expresssion. Leukemia 2001; 15: 406–414.
San Miguel JF, Garcia-Sanz R, Gonzalez M, Moro MJ, Hernandez JM, Ortega F et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995; 85: 448–455.
Chang CC, Cleveland RP . Decreased CD10-positive mature granulocytes in bone marrow from patients with myelodysplastic syndrome. Arch Pathol Lab Med 2000; 124: 1152–1156.
Nutt SL, Morrison AM, Dorfler P, Rolink A, Busslinger M . Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. EMBO J 1998; 17: 2319–2333.
Carter TL, Watt PM, Kumar R, Burton PR, Reaman GH, Sather HN et al. Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse. Blood 2001; 97: 572–574.
Acknowledgements
MD Tabernero is supported by a grant from the Ministerio de Ciencia y Tecnología MCYT, (programa Ramón y Cajal), Madrid, Spain. JM Sayagues and AB Espinosa are supported by grants 02/9103 and 02/0010 from the Ministerio de Sanidad y Consumo (Madrid, Spain).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Primo, D., Tabernero, M., Perez, J. et al. Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. Leukemia 19, 713–720 (2005). https://doi.org/10.1038/sj.leu.2403714
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403714
Keywords
This article is cited by
-
Jak2/STAT6/c-Myc pathway is vital to the pathogenicity of Philadelphia-positive acute lymphoblastic leukemia caused by P190BCR-ABL
Cell Communication and Signaling (2023)
-
Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia
Journal of Hematology & Oncology (2016)
-
Flow cytometry in the diagnosis and monitoring of acute leukemia in children
Journal of Hematopathology (2015)
-
An adult B-cell precursor acute lymphoblastic leukemia with multiple secondary cytogenetic aberrations
Molecular Cytogenetics (2014)